Persistence of Antibody After Administration of Monovalent and Combined Live Attenuated Measles, Mumps, and Rubella Virus Vaccines

PEDIATRICS ◽  
1978 ◽  
Vol 61 (1) ◽  
pp. 5-11
Author(s):  
Robert E. Weibel ◽  
Eugene B. Buynak ◽  
Arlene A. McLean ◽  
Maurice R. Hilleman
Keyword(s):  
Antibody Titer ◽  
Virus Vaccine ◽  
Rubella Virus ◽  
Natural Infection ◽  
Neutralizing Antibody ◽  
Mumps Virus ◽  
Rubella Vaccine ◽  
Mumps Vaccine ◽  
Antibody Persistence ◽  
Substantial Decline

Hemagglutination-inhibiting antibodies were retained in comparable levels eight years after vaccination with Enders' original Edmonston and more attenuated Moraten (Attenuvax) and Schwarz line measles vaccines. Neutralizing antibody persisted without substantial decline in titer for at least 9.5 years after administration of Jeryl Lynn mumps virus vaccine (Mumpsvax). Antibodies were retained without important decline in children and adults for at least 7.5 and 7 years, respectively, after administration of HPV-77 duck-modified rubella vaccine (Meruvax). The patterns of antibody persistence 7.5 years after administration of combined measles-mumps-rubella (M-M-R) and mumps-rubella (Biavax) vaccines, 6 years after administration of measles-rubella vaccine (M-R-VAX), and 4 years after administration of measles-mumps vaccine (M-M-VAX) were the same as for the monovalent vaccines, indicating no alteration in the retention of immunity. Subclinical reinfection evidenced by increase in homologous antibody titer was observed to follow vaccination the same as occurs after natural infection.

PERSISTENCE OF IMMUNITY FOLLOWING MONOVALENT AND COMBINED LIVE MEASLES, MUMPS, AND RUBELLA VIRUS VACCINES

PEDIATRICS ◽  
1973 ◽  
Vol 51 (3) ◽  
pp. 467-475
Author(s):  
Robert E. Weibel ◽  
Eugene B. Buynak ◽  
Joseph Stokes ◽  
Maurice R. Hilleman
Keyword(s):  
Virus Vaccine ◽  
Rubella Virus ◽  
Protective Immunity ◽  
Neutralizing Antibody ◽  
Mumps Virus ◽  
Rubella Vaccine ◽  
Antibody Persistence ◽  
Comparable Level ◽  
Substantial Decline

Neutralizing antibody following Jeryl Lynn mumps virus vaccine persisted for at least six years after vaccination without substantial decline in titer, and protective immunity was solidly retained through the sixth observation year. Hemagglutination-inhibiting antibodies following vaccination with Enders' original Edmonston and more attenuated Moraten and Schwarz lines measles vaccines were retained in comparable level through the fourth year. Antibody following HPV-77 duck rubella vaccine was retained without important decline for at least 3½ years. The pattern for antibody persistence following combined measles-mumps-rubella and mumps-rubella vaccine measured at three years and for measles-rubella vaccine measured at two years was the same as for the monovalent vaccines indicating no alteration in the retention of immunity. None of the children in this study lost his antibody completely. Subclinical reinfection evidenced by antibody increase was commonly seen in vaccinated persons.

PERSISTENCE OF IMMUNITY FOUR YEARS FOLLOWING JERYL LYNN STRAIN LIVE MUMPS VIRUS VACCINE

PEDIATRICS ◽  
1970 ◽  
Vol 45 (5) ◽  
pp. 821-826
Author(s):  
Robert E. Weibel ◽  
Eugene B. Buynak ◽  
Joseph Stokes ◽  
Maurice R. Hilleman
Keyword(s):  
Virus Vaccine ◽  
Neutralizing Antibody ◽  
Mumps Virus ◽  
School Year ◽  
Antibody Persistence ◽  
Substantial Decline ◽  
Mumps Infection

Neutralizing antibody following Jeryl Lynn strain live mumps virus vaccine persisted for at least 4 years following vaccination, without substantial decline in titer. The pattern for mumps antibody persistence after vaccine paralleled that following natural mumps infection. No instances of mumps occurred among 18 vaccinated children in families who were exposed to infection by contact with natural mumps cases which occurred in siblings 32 to 44 months after the vaccine had been given. Similarly, no instances of mumps occurred among 25 children in classrooms who were exposed to natural mumps during the fourth school year following vaccination. The available data indicate that the protection afforded by the mumps virus vaccine will be lasting.

Long-Term Follow-up for Immunity After Monovalent or Combined Live Measles, Mumps, and Rubella Virus Vaccines

PEDIATRICS ◽  
1975 ◽  
Vol 56 (3) ◽  
pp. 380-387
Author(s):  
Robert E. Weibel ◽  
Eugene B. Buynak ◽  
Arlene A. McLean ◽  
Maurice R. Hilleman
Keyword(s):  
Rubella Virus ◽  
Protective Immunity ◽  
Human Subjects ◽  
Natural Infection ◽  
Rubella Vaccine ◽  
Mumps Vaccine ◽  
Long Term Follow Up ◽  
Substantial Decline

Antibody in human subjects persisted without substantial decline for 8 years after mumps vaccine (Jeryl Lynn), for 6 years after measles (Attenuvax), for 5½ years after rubella vaccine (HPV-77 duck), for 5 years after measles-mumps-rubella and mumps-rubella combined vaccines, for 4 years after measles and rubella, and for 2 years after measles-mumps vaccines, the longest periods tested. Protective immunity against mumps illness persisted through the eighth year. The patterns for antibody following vaccination parallel those for natural infection and indicate that immunity will be lasting. Subclinical reinfection evidenced by antibody increase was commonly seen in persons who had been vaccinated, much as follows the natural infection.

scholarly journals The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901

2021 ◽  
Author(s):  
Szu-Min Hsieh ◽  
Shan-chwen Chang ◽  
Hao-Yuan Cheng ◽  
Shin-Ru Shih ◽  
Chia En Lien
Keyword(s):  
Clinical Study ◽  
Antibody Titer ◽  
Subunit Vaccine ◽  
Booster Dose ◽  
Phase 1 ◽  
Neutralizing Antibody ◽  
Dose Schedule ◽  
Protein Subunit ◽  
Antibody Persistence

AbstractIn this extension of the phase 1 clinical study, we report the immunogenicity and reactogenicity of the booster dose of a COVID-19 vaccine, MVC-COV1901, administered six months after the completion of the primary two dose schedule. Antibody persistence was detected at 6 months after the second dose of MVC-COV1901, albeit at reduced levels. At 28 days after the booster dose, the neutralizing antibody titer was 1.7-fold higher compared to the previous peak at 2 weeks after the second dose. These data demonstrated the safety and immunogenicity of booster shot of MVC-COV1901 after the primary schedule of the vaccine.

EXPERIENCES WITH JERYL LYNN STRAIN LIVE ATTENUATED MUMPS VIRUS VACCINE IN A PEDIATRIC OUTPATIENT CLINIC

PEDIATRICS ◽  
1967 ◽  
Vol 40 (5) ◽  
pp. 798-803
Author(s):  
M. L. Young ◽  
B. Dickstein ◽  
R. E. Weibel ◽  
J. Stokes ◽  
E. B. Buynak ◽  
...  
Keyword(s):  
Virus Vaccine ◽  
Outpatient Clinic ◽  
Seroconversion Rate ◽  
Neutralizing Antibody ◽  
Mumps Virus ◽  
Antibody Responses ◽  
Memorial Hospital ◽  
Controlled Study ◽  
Clinical Reaction ◽  
Pediatric Clinic

A controlled study of B level Jeryl Lynn strain live attenuated mumps virus vaccine was carried out during June through November 1966 in the pediatric outpatient clinic of the John F. Kennedy Memorial Hospital in Philadelphia. Altogether, 924 children were given the vaccine and paired sera were taken from a sample of 101 of the children for purpose of measuring initial serologic status for mumps and for ascertaining antibody responses. Based on the results obtained, it was estimated that roughly 410 of the children who were vaccinated were initially seronegative for mumps. Forty-eight of the 49 children sampled who were initially without antibody developed mumps antibody following vaccination, giving a seroconversion rate of 98%. The vaccinated children presented no evidence of fever or other untoward clinical reaction referable to the vaccine. It was concluded that the vaccine was safe, highly efficacious in stimulating the production of neutralizing antibody, and readily applicable to the routine pediatric clinic.

ACUTE HEMANGIOMA-LIKE LESIONS ASSOCIATED WITH ECHO VIRAL INFECTIONS

PEDIATRICS ◽  
1969 ◽  
Vol 44 (4) ◽  
pp. 498-502
Author(s):  
James D. Cherry ◽  
John E. Bobinski ◽  
Frances L. Horvath ◽  
George D. Comerci
Keyword(s):  
Antibody Titer ◽  
Viral Infections ◽  
Neutralizing Antibody ◽  
The Other ◽  
Rubella Vaccine ◽  
Vaccine Trials ◽  
Vascular Dilatation ◽  
Laboratory Surveillance ◽  
The Individual

In the summer and fall of 1968, during clinical rubella vaccine trials, clinical and laboratory surveillance of acute exanthematous illnesses was carried out. During this period, four children with acute transitory hemangioma-like lesions were noted; ECHO 25 virus was isolated from two of these patients and ECHO 32 was recovered from the other two children. All four children had four- fold or greater neutralizing antibody titer rises to their respective viruses. It is suggested that the individual lesions of the reported exanthems have a pathogenesis similar to other enteroviral maculopapular eruptions, except that vascular dilatation is arteriolar as well as capillary.

Current Status of Mumps and Mumps Vaccine in the United States

PEDIATRICS ◽  
1978 ◽  
Vol 62 (6) ◽  
pp. 965-969
Author(s):  
Gregory F. Hayden ◽  
Stephen R. Preblud ◽  
Walter A. Orenstein ◽  
J. Lyle Conrad
Keyword(s):  
Public Health ◽  
United States ◽  
Virus Vaccine ◽  
The United States ◽  
Mumps Virus ◽  
Current Status ◽  
Live Virus ◽  
Control Programs ◽  
Mumps Vaccine ◽  
Low Levels

Reported mumps in the United States has declined to all-time low levels following the increasingly widespread use of mumps-virus vaccine. Mumps vaccine has proven safe and effective. Its incorporation into combined live-virus vaccines, especially measles-mumps-rubella, has made mumps vaccination a practical and economically feasible component of routine immunization activities. Because of the favorable experience to date with mumps vaccine and the associated drop in mumps morbidity and mortality, mumps control programs likely will receive increasing public health attention in the coming years.

Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults

Vaccine ◽  
2018 ◽  
Vol 36 (38) ◽  
pp. 5732-5737 ◽  
Author(s):  
Huong Q. McLean ◽  
Amy Parker Fiebelkorn ◽  
Adaeze Ogee-Nwankwo ◽  
LiJuan Hao ◽  
Laura A. Coleman ◽  
...  
Keyword(s):  
Young Adults ◽  
Antibody Response ◽  
Rubella Virus ◽  
Neutralizing Antibody ◽  
Rubella Vaccine
Sign in / Sign up

Export Citation Format

Share Document